Skip to main content
ArticleOPEN ACCESS

Correction to: Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal (PharmacoEconomics, (2019), 37, 5, (645-654), 10.1007/s40273-018-0720-8)

PharmacoEconomics
DOI: 10.1007/s40273-018-0743-1
0Citations
Citations of this article
3Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The title of the article should read: Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. The original article was corrected

Cite

CITATION STYLE

APA

Claxton, L., O’Connor, J., Woolacott, N., Wright, K., & Hodgson, R. (2019, May 1). Correction to: Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal (PharmacoEconomics, (2019), 37, 5, (645-654), 10.1007/s40273-018-0720-8). PharmacoEconomics. Springer International Publishing. https://doi.org/10.1007/s40273-018-0743-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free